Furthermore, we tested a panel of cancer cell lines driven by either hyperactivating mutants or amplification in EGFR or HER2 and found no similar hyperactivation of transmembrane RTK signaling upon oncogene inhibition, further linking signal suppression specifically to cytoplasmic RTK assemblies and not simply to hyperactivated RTKs (Supplementary Fig. S7C, D). The gene discussed is ERBB2; the disease is cancer.